TWM
BCAX

Thrive Wealth Management’s Bicara Therapeutics BCAX Stock Holding History

Thrive Wealth Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,344
Closed -$206K – 271
2026
Q1 		$206K Buy
+10,344
New +$178K 0.03% 221

Other funds holding BCAX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Thrive Wealth Management's BCAX Position: Q2 2026 in Review

Thrive Wealth Management sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 10,344 shares — an estimated $206K sold.

Thrive Wealth Management first reported a position in BCAX in Q1 2026 and held it in 1 quarter. The position peaked at $206K in Q1 2026. 5 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Thrive Wealth Management reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Thrive Wealth Management sold 10,344 Bicara Therapeutics shares in Q2 2026, an estimated $206K.
  • Thrive Wealth Management first reported a position in Bicara Therapeutics in Q1 2026 and held it in 1 quarter.
  • Thrive Wealth Management's Bicara Therapeutics position peaked at $206K in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Thrive Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.